Market cap
$1,058 Mln
Revenue (TTM)
$-- Mln
P/E Ratio
--
P/B Ratio
3.6
Div. Yield
0 %
Quality Score
/10
Growth Score
/10
Valuation Score
/10
Momentum Score
/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-- Mln
-
ROE
-0.6 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-5.2
-
Debt to Equity
--
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
62,806,000
Years Aggregate
CFO
$--
EBITDA
$--
Net Profit
$--
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
VectivBio Holding AG (VECT)
| 94.5 | -0.3 | 96.0 | 180.4 | -- | -- | -- |
|
BSE Sensex*
| -10.8 | -0.6 | -1.7 | -8.5 | 6.4 | 7.6 | 11.0 |
|
Company
|
2022
|
|---|---|
|
VectivBio Holding AG (VECT)
| 76.5 |
|
BSE Sensex
| 4.4 |
|
BSE Sensex
| 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout VectivBio Holding AG (VECT)
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of... glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc. Read more
-
Founder, CEO & Director
Dr. Luca Santarelli M.D.
-
Founder, CEO & Director
Dr. Luca Santarelli M.D.
-
Headquarters
Basel
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for VectivBio Holding AG (VECT)
What is the current share price of VectivBio Holding AG (VECT) Today?
The share price of VectivBio Holding AG (VECT) is $16.85 (NASDAQ) as of 17-Jul-2023 09:30 EDT. VectivBio Holding AG (VECT) has given a return of 180.37% in the last 1 years.
What is the current PB & PE ratio of VectivBio Holding AG (VECT)?
Since, TTM earnings of VectivBio Holding AG (VECT) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-2.49
|
1.09
|
|
2021
|
-1.52
|
1.14
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
What is the 52 Week High and Low of VectivBio Holding AG (VECT)?
The 52-week high and low of VectivBio Holding AG (VECT) are Rs -- and Rs -- as of 13-Jun-2026.
What is the market cap of VectivBio Holding AG (VECT)?
VectivBio Holding AG (VECT) has a market capitalisation of $ 1,058 Mln as on 17-Jul-2023. As per SEBI classification, it is a company.
Should I invest in VectivBio Holding AG (VECT)?
Before investing in VectivBio Holding AG (VECT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.